Biopharmaceutical company Immunic has secured regulatory approval from Germany’s BfArM to conduct a Phase II clinical trial, CALVID-1, of IMU-838 in Covid-19 patients.
IMU-838 is an oral selective immune modulator designed to block the intracellular metabolism of activated immune cells by inhibiting the dihydroorotate dehydrogenase (DHODH) enzyme .
The prospective, multi-centre, randomised, placebo-controlled, double-blind CALVID-1 trial will assess efficacy, safety and tolerability of IMU-838 in around 230 patients with moderate Covid-19 at 10-35 sites in Europe and the US.
Dosing is set to start this month, with top-line results expected later this year.
Immunic chief medical officer Andreas Muehler said: “IMU-838’s profile, as an orally available DHODH inhibitor that employs a host-based mode of action, thereby providing broad-spectrum antiviral activity, makes it a unique, potential therapeutic option, which may be applicable as either a standalone or combination therapy.
“All Phase II preparatory activities have been completed and we anticipate beginning the trial in short order.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
The company said that IMU-838 demonstrated preclinical activity against SARS-CoV-2, which causes Covid-19. It was found to prevent replication of clinical isolates of the virus.
As well as an oral treatment for Covid-19, CALVID-1 is expected to allow the use of IMU-838 to treat current and any future pandemic threats. Patients will be given 22.5mg of IMU-838 or placebo twice daily, for 14 consecutive days.
The primary endpoint will be the proportion of patients not requiring invasive ventilation during the study period. Secondary endpoints include duration of hospitalisation and intensive care unit (ICU) treatment, 28-day all-cause mortality, time to clinical improvement and viral titer reduction.
If clinical activity of IMU-838 is validated by the Independent Data Monitoring Committee, the trial could be expanded into a confirmatory Phase III study.